Literature DB >> 32583494

Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Hikmet Akkiz1, Brian I Carr2, Harika G Bag2, Ümit Karaoğullarından1, Kendal Yalçın3, Nazim Ekin3, Ayşegül Özakyol4, Engin Altıntaş5, Hatice Y Balaban6, Halis Şimşek6, Ahmet Uyanıkoğlu7, Ayhan Balkan8, Sedef Kuran1, Oğuz Üsküdar1, Yakup Ülger1, Burak Güney1, Anil Delik1.   

Abstract

INTRODUCTION: Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important.
OBJECTIVE: To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients.
METHODS: We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival.
RESULTS: Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3-fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors.
CONCLUSIONS: Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.
© 2020 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32583494      PMCID: PMC7758189          DOI: 10.1111/ijcp.13593

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  51 in total

1.  Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.

Authors:  Hikmet Akkiz; Brian I Carr; Kendal Yalçın K; Vito Guerra; Sedef Kuran; Engin Altıntaş; Oğuz Üsküdar; Ümit Karaoğullarından; Ayşegül Özakyol; Salih Tokmak; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Tuğsan Ballı; Ali Demir; Burcu Arslan; Figen Doran
Journal:  Oncology       Date:  2017-12-06       Impact factor: 2.935

2.  Inflammatory microenvironment and expression of chemokines in hepatocellular carcinoma.

Authors:  Ke-Qi Han; Xue-Qun He; Meng-Yu Ma; Xiao-Dong Guo; Xue-Min Zhang; Jie Chen; Hui Han; Wei-Wei Zhang; Quan-Gang Zhu; Hua Nian; Li-Jun Ma
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

3.  C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma.

Authors:  Sha She; Yi Xiang; Min Yang; Xiangchun Ding; Xiaoyan Liu; Lina Ma; Qing Liu; Bin Liu; Zhenhui Lu; Shiying Li; Yi Liu; Xiaoping Ran; Xiaoming Xu; Huaidong Hu; Peng Hu; Dazhi Zhang; Hong Ren; Yixuan Yang
Journal:  Int J Oncol       Date:  2015-06-10       Impact factor: 5.650

4.  Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.

Authors:  Valerie Chew; Charlene Tow; Marissa Teo; Hing Lok Wong; Jasmine Chan; Adam Gehring; Marie Loh; Alexandre Bolze; Richard Quek; Victor K M Lee; Kang Hoe Lee; Jean-Pierre Abastado; Han Chong Toh; Alessandra Nardin
Journal:  J Hepatol       Date:  2009-08-03       Impact factor: 25.083

5.  Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis.

Authors:  Shao-Hua Li; Qiao-Xuan Wang; Zhong-Yuan Yang; Wu Jiang; Cong Li; Peng Sun; Wei Wei; Ming Shi; Rong-Ping Guo
Journal:  World J Gastroenterol       Date:  2017-05-07       Impact factor: 5.742

6.  Novel Prognostic Nomograms Based on Inflammation-Related Markers for Patients with Hepatocellular Carcinoma Underwent Hepatectomy.

Authors:  Yifei Wang; Kaiyu Sun; Jingxian Shen; Bin Li; Ming Kuang; Qinghua Cao; Sui Peng
Journal:  Cancer Res Treat       Date:  2019-03-11       Impact factor: 4.679

Review 7.  Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance.

Authors:  Anne E Tuomisto; Markus J Mäkinen; Juha P Väyrynen
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

Review 8.  Inflammation and cancer.

Authors:  Mariko Murata
Journal:  Environ Health Prev Med       Date:  2018-10-20       Impact factor: 3.674

9.  C-Reactive Protein Promotes the Expansion of Myeloid Derived Cells With Suppressor Functions.

Authors:  Rachel V Jimenez; Valeriya Kuznetsova; Ashley N Connelly; Zdenek Hel; Alexander J Szalai
Journal:  Front Immunol       Date:  2019-09-18       Impact factor: 7.561

Review 10.  Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Mu-Xing Li; Xin-Yu Bi; Zhi-Yu Li; Zhen Huang; Yue Han; Jian-Guo Zhou; Jian-Jun Zhao; Ye-Fan Zhang; Hong Zhao; Jian-Qiang Cai
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more
  3 in total

1.  Effect of storage temperature and time on erythrocyte sedimentation rate.

Authors:  Qi-Lei Hu; Zuo-Jie Li; Li Lin; Liang Zhang; Yin-Jiang Lv; Li-Feng Wu; Mei-Yun Chen
Journal:  Eur J Med Res       Date:  2022-05-28       Impact factor: 4.981

2.  Prognostic Impact of Serum CRP Level in Head and Neck Squamous Cell Carcinoma.

Authors:  Yaoting Zhang; Dongsheng Gu
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

3.  Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes.

Authors:  B I Carr; V Guerra; R Donghia; S Yilmaz
Journal:  Ann Med Surg (Lond)       Date:  2021-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.